Study Phase 1

A Single-Dose, Open-Label, Randomized, Parallel-Group Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Paliperidone Palmitate 3-Month Formulation in Subjects With Schizophrenia

  • 1 CSR Summary Not Available
  • 1 NCT01559272
  • 1 Primary Citation Trial has yet to be published
  • Data Specification Not Available

Trial Information

Generic NamePaliperidoneProduct NameINVEGA®Therapeutic AreaNervous System DiseasesEnrollment328% FemaleN/A% WhiteN/A
Product ClassAtypical AntipsychoticsSponsor Protocol NumberR092670PSY1005Data PartnerJohnson & JohnsonCondition StudiedSchizophreniaMean/Median Age (Years)N/A

Supporting Documentation

  • Collected Datasets Available
  • Protocol with Amendments Available
  • Clinical Study Report Available

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.